Research
Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial
Nature · By Daniel J. Green ·
The Brief
- A randomized controlled trial published in Nature Medicine compared people receiving tirzepatide for obesity with and without resistance exercise.
- Participants who did resistance exercise while on tirzepatide lost less lean mass than those receiving tirzepatide alone.
- The paper was published online on 9 November 2026 (doi:10.1038/s41591-026-04752-5).
Why it matters
Tirzepatide-driven weight loss can include lean mass loss, and this trial suggests resistance exercise may reduce that loss, which matters for how obesity treatment is monitored and combined with exercise.
Who’s affected
- clinicians treating obesity with tirzepatide
- obesity and exercise science researchers
- #obesity
- #tirzepatide
- #resistance-exercise
- #lean-mass
- #randomized-trial
Nature Medicine, Published online: 09 November 2026; doi:10.1038/s41591-026-04752-5 Participants undergoing resistance exercise while receiving tirzepatide lost less lean mass than participants receiving tirzepatide alone.
Timeline
Published online in Nature Medicine
nature.com
Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial